Judge O’Malley Nomination Moved Out of Senate Judiciary Committee to Full Senate

September 27th, 2010

The Senate Judiciary Committee held a vote on Judge Kathleen O’Malley last Thursday during its business meeting.  By voice vote of the committee members, Judge O’Malley’s nomination was approved unanimously by the quorum of senators.  Her nomination will now move to the full Senate for a vote at a later date.

The Senate Judiciary Committee has not yet held a hearing on nominee Edward C. DuMont for a second vacancy on the Federal Circuit. 

A third vacancy still has no nominee from the White House.

During the committee meeting, Chairman Leahy noted that the Federal Circuit currently has three vacancies and that the committee has to “get moving” on the pending nominations.  The D.C. Circuit apparently has four vacancies.

You can watch the webcast of the committee meeting here: [Watch Committee Meeting].  Judge O’Malley’s nomination is discussed at about the 20:49 minute and 46:10 minute marks.

Feelin’ Groovy — Spine Solutions, Inc. et al. v. Medtronic Sofamor Danek USA,Inc. et al.

September 24th, 2010

UPDATED 9/25/2010

Spine Solutions, Inc., et al. v. Medtronic Sofamor Danek USA, Inc. et al., 2009-1538 (Fed. Cir. September 9, 2010) is an interesting case in that it deals with “adapted to” language and “operative engagement” language.

6936071_intervertebral_implant1-fig-2

Claim 1 of the 6,936,071 patent, the only independent claim at issue, reads as follows:

 

An intervertebral implant insertable between ad-jacent vertebrae, comprising,

 

an upper part having an upper surface for engaging a vertebrae and a lower surface which includes a rounded portion,

 

a lower part having a lower surface for engaging a vertebrae and an upper surface portion in operative engagement with the rounded portion of the upper part,

 

said implant being constructed to be the sole im-plant in its intervertebral space,

 

the implant having a lead end which leads as the implant is inserted along a path into the intervertebral space and a trailing end opposite the lead end, and lateral planes which pass through the outermost boundaries of the implant and parallel to the said path, and

 

a single anchor on each of the upper surface of the upper part and the lower surface of the lower part, each said anchor being elongated, having a height greater than its width, and located along a line parallel to said path, the two anchors lying essentially in the same vertical plane, which plane is essentially midway between said lateral planes,

 

each said anchor being adapted to enter a groove in the adjacent vertebrae as the implant moves along said path into the intervertebral space, to anchor its respective part to the vertebrae which its surface engages.

The issue with respect to the “adapted to” language was whether the written description of the patent had been satisfied for the claim language “adapated to enter a groove.” This language was added after filing the application and according to the appellant had no basis in the specification. The court decided this isssue as follows:

Medtronic asserts that the district court erred in granting summary judgment that the ’071 patent contains adequate written description to support the limitation “single anchor . . . adapted to enter a groove.” We review a grant of summary judgment de novo, reapplying the standard applicable at the district court. Young v. Lu-menis, Inc., 492 F.3d 1336, 1345 (Fed. Cir. 2007). Sum-mary judgment is appropriate “if the pleadings, depositions, answers to interrogatories, and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving party is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(c). “Compliance with the written description requirement is a question of fact but is ame-nable to summary judgment in cases where no reasonable fact finder could return a verdict for the non-moving party.” PowerOasis, Inc. v. T-Mobile USA, Inc., 522 F.3d 1299, 1307 (Fed. Cir. 2008).

Claim 1 recites that the “single anchor” is “adapted to enter a groove in the adjacent vertebrae.” ’071 patent col.7 ll.3-10 (emphasis added). Medtronic argued that the written description does not disclose the “adapted to enter a groove” limitation. SSI argues that the ’071 patent necessarily discloses anchors that are “adapted to enter a groove” because it discloses that the adjacent vertebrae rest on the support faces of the intervertebral implant after insertion. The district court granted summary judgment holding that the claim was adequately sup-ported by the written description. We see no error in this judgment.

Medtronic is correct that the ’477 patent disclosure was not incorporated by reference and therefore cannot provide the disclosure of the “adapted to enter a groove” limitation. In the two pages Medtronic devotes to this issue, it argues that the patent makes no mention of grooves. See, e.g., Medtronic’s Br. at 37 (“patent’s failure to disclose any information concerning the grooves located in the vertebrae and their interaction with the anchor is a prime example of SSI’s attempt to expand its claims beyond its disclosures”); Medtronic’s Reply Br. at 8 (argu-ing that the patent diagrams do not show any grooves). Because the claims at issue relate to the implant and do not cover the groove itself, applicants were not required to disclose grooves or how grooves should be formed or cut. The limitation at issue does not recite cutting a groove into vertebrae, or even inserting an anchor into a groove; rather, it recites “a single anchor . . . adapted to enter a groove.” The issue for written description purposes is whether a person of skill in the art would understand the ’071 patent to describe a single anchor that is adapted to enter a groove. See Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010) (en banc) (“the test for sufficiency [of the written description requirement] is whether the disclosure of the application relied upon reasonably conveys to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date”).

We see no error in the district court’s determination that there is no genuine dispute of material fact; the specification describes the claimed “single anchor” as necessarily being “adapted to enter a groove.” The disclosure of the shape of the anchor in combination with its placement adequately describes an anchor adapted to enter a groove. The specification discloses that each of the top and bottom parts of the implant has a support face that includes a single anchor. ’071 patent col.3 ll.56-58, col.4 ll.9-12, figs. 1-7. These anchors affix the upper and lower parts into the adjacent vertebrae such that the end face of each vertebrae “rests . . . on the support face” of the corresponding part of the implant. Id. col.3 ll.58-60, col.5 ll.59-64. Thus, the specification discloses that the single anchor enters the adjacent vertebrae in such a way that the vertebrae “rest” on the support faces of the top and bottom parts of the implant. For such direct contact between the implant and vertebrae to occur, the single anchor must be entirely inserted into the adjacent vertebrae: that is, the anchors must be fully inserted into a “groove” of some type, whether that groove is pre-cut or formed by the anchor itself (e.g., by a “self-cutting” an-chor). The specification, therefore, discloses that the single anchor is inserted into a vertebral groove. The record lacks adequate evidence to create a genuine dis-pute over whether the specification discloses that the anchors are “adapted to enter a groove.” The fact that the specification never mentions the word groove is not suffi-cient to create a genuine dispute of material fact.

We agree with the district court that the specification of the ’071 patent provides adequate written description to support the “single anchor . . . adapted to enter a groove” limitation. Therefore, we affirm the court’s grant of SSI’s motion for partial summary judgment dismissing Medtronic’s 35 U.S.C. § 112 defenses.

The parties spent a good portion of oral argument discussing the “adapted to enter a groove” issue. You can listen to Appellant’s argument [Here], Appellee’s argument [Here], and Appellant’s rebuttal argument [Here].

Another issue concerned the claim construction of the language “operative engagement.” The Appellant argued as follows: [Listen]. The Appellee did not have a chance to discuss this issue during oral argument.

The panel had the following to say in regard to “operative engagement”:

Medtronic asserts that the district court erred in con-struing the claim term “operative engagement.” Claim construction is a matter of law, and we review the court’s claim construction without deference. Cybor Corp. v. FAS Techs., Inc., 138 F.3d 1448, 1451 (Fed. Cir. 1998) (en banc). In doing so, we are mindful of the principle that “the claims of a patent define the invention to which the patentee is entitled the right to exclude.” Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed. Cir. 2005) (en banc). We read the claims “in view of the specification,” which is “the single best guide to the meaning of a disputed term.” Id. at 1315.

Claim 1 recites the limitation of “a lower part having a lower surface for engaging a vertebrae and an upper surface portion in operative engagement with the rounded portion of the upper part.” ’071 patent col.6 ll.60-62 (emphasis added). At claim construction, Medtronic proposed construing “operative engagement” to mean “the interaction between the pivot insert and the rounded portion of the upper part.” Claim Construction Order, 2008 U.S. Dist. LEXIS 116648, at *18. The court ob-served that although the preferred embodiment of the ’071 patent has a pivot, claim 1 does not recite such a limitation: rather, claim 1 recites only an upper and a lower part that are “in operative engagement” with each other. The court also found that claim differentiation weighed against reading a pivot limitation into claim 1, because various dependent claims add limitations relating to a two-piece lower part with a pivot insert. Therefore, the court adopted SSI’s proposed construction, construing “operative engagement” as “permitting movement (for example pivotability).” Id. at *23.

     Medtronic asserts that the court erred in construing “operative engagement” as not incorporating a pivot insert. According to Medtronic, the only “engagement” disclosed by the specification occurs between the upper part and the pivot insert, not between the upper and lower parts. SSI asserts that the court’s construction is correct because the plain language of the claim does not limit the invention to the preferred three-piece embodi-ment.

We agree with SSI that the court correctly construed “operative engagement.” The language of the limitation is straightforward: the lower part of the implant engages “operatively” with the rounded portion of the upper part. Given that the claimed invention is an intervertebral implant designed to replace a disc in a spinal column, “operative engagement” must be engagement such that the upper and lower parts of the implant can move rela-tive to each other; otherwise, the implant would be rigid and would inhibit movement of the adjacent vertebrae. Thus, the court correctly determined that “operative engagement” relates to permitting movement. The court also did not err in identifying pivotability as an example type of movement; the ’071 patent specifically discloses pivotability in association with the preferred embodiment. However, nothing in the claim suggests that the upper part of the implant must be specifically engaged with a pivot insert, as opposed to the lower part of the implant. To the contrary, the claim indicates that the upper and lower parts are engaged with each other directly. ’071 patent col.6 ll.60-62 (“a lower part having . . . an upper surface portion in operative engagement with the rounded portion of the upper part”). Therefore, the court did not err in construing “operative engagement” as “permitting movement (for example pivotability).”

     Medtronic asserts, in the alternative, that under the court’s construction claim 1 is invalid for failure to comply with the written description requirement. Therefore, Medtronic argues, the court erred in granting summary judgment that the ’071 patent contains adequate written description to support the limitation “lower part having . . . an upper surface portion in operative engagement with the rounded portion of the upper part.” Medtronic argues that the ’071 patent only describes a three-piece device with a separate pivot insert, not a two-piece device that permits movement between the top and bottom parts. However, Figures 3 and 6 of the ’071 patent illustrate the implant outside the intervertebral space (i.e., prior to insertion) and show the pivot insert as embedded in the lower part. Additionally, the evidence at summary judg-ment included deposition testimony from Medtronic’s expert that a person of skill in the art would have known that an implant having a lower plate with an embeddable pivot insert—such as that disclosed by the ’071 patent—could have been assembled prior to insertion and inserted into the patient as a two-piece device. Medtronic does not point to any evidence rebutting this testimony. Therefore, we agree with the district court that a person of skill in the art would have understood the ’071 patent to describe an implant that could be pre-assembled prior to insertion, such that the upper surface of the lower part is “opera-tively engaged” with the lower surface of the upper part.
Medtronic contends that the ’071 patent does not de-scribe a two-piece implant because the ’071 patent ac-tively disparages the two-piece design of the ’477 patent. In discussing the two-piece design of the ’477 patent, the ’071 patent notes that it is “particularly difficult” to achieve a minimum structural height for an implant if the pivot is embedded prior to insertion. Id. col.1 ll.11-19. However, this does not rise to the level of an express disclaimer sufficient to limit the scope of the claims; “[d]isavowal requires expressions of manifest exclusion or restriction, representing a clear disavowal of claim scope.” Epistar Corp. v. ITC, 566 F.3d 1321, 1335 (Fed. Cir. 2009). Further, claim 1 is not directed to the height-minimizing embodiment. The originally-filed claims recited limitations directed to “protrusions and recesses . . . which are offset laterally from one another in such a way that . . . [the upper and lower parts] mesh with one an-other,” see J.A. 17167; claim 1 as issued recites no such limitation.

You can read the court’s opinion here: [Read].
You can listen to the entire oral argument here: [Listen].

You can review extrinsic evidence here:

Prior Art Used to Construe Claim

September 21st, 2010

In Laryngeal Mask Co. Ltd v. Ambu A/S, 2010-1028 (Fed. Cir. September 21, 2010), the Federal Circuit dealt with some complicated claim construction issues.  One issue concerned the meaning of the word “backplate” used in a laryngeal mask patent.  The oral argument for this case was featured in an earlier post as the Oral Argument of the Month [Link]. 

What caught my eye in today’s opinion was the use of prior art patents as a guide to construe a claim term.  The court wrote:

Although there was no dictionary or treatise defini-tion introduced for backplate, there are two prior art patents also related to laryngeal mask devices which use the term. U.S. Patent No. 5,355,879 (’879 patent); U.S. Patent No. 5,305,743 (’743 patent). Both prior art patents list the same inventor as the patent at issue, Dr. Brain. Both of these patents disclose a backplate, but neither includes a tube joint. This prior art use of the term would further inform one of skill in the art as to the common meaning of the term backplate.

The term backplate has a somewhat self-descriptive nature. As the prior art patents indicate it is the plate on the back. In light of the claims, specification, prosecution history, and prior art patents, we conclude that one of skill in the art would understand the claimed backplate to be “the relatively rigid mask structure surrounded by the cuff.” We conclude that one of skill in the art would not conclude that the backplate must have a tube joint. We also conclude that the inventor did not act as his own lexicographer here and clearly require the backplate to have a tube joint. Because the district court’s judgment of noninfringement was based on an erroneous claim con-struction, we vacate that judgment and remand for fur-ther proceedings.

 

The court’s statement  “in view of the claims, specification, prosecution history, and prior art patents” is a little redundant because the prior art patents were cited during the prosecution history — therefore under Phillips v. AWH, 415 F.3d 1303 (Fed. Cir. 2005) those cited prior art patents actually form part of the prosecution history.  See Phillips at 1317 (“The prosecution history, which we have designated as part of the “intrinsic evidence,” consists of the complete record of the proceedings before the PTO and includes the prior art cited during the examination of the patent. Autogiro, 384 F.2d at 399.”).

This case is reminiscent of Arthur A. Collins, Inc. v. Northern Telecom Ltd., 216 F.3d 1042 (Fed. Cir. 2000), where the court said:

Even when prior art is not cited in the written description or the prosecution history, it may assist in ascertaining the meaning of a term to a person skilled in the art. See Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1584, 39 USPQ2d 1573, 1578 (Fed.Cir.1996). When prior art that sheds light on the meaning of a term is cited by the patentee, it can have particular value as a guide to the proper construction of the term, because it may indicate not only the meaning of the term to persons skilled in the art, but also that the patentee intended to adopt that meaning.

You can read the entire Laryngeal Mask opinion here: [Read].

Merit Systems Protection Board to Conduct First Oral Argument in 27 Years

September 20th, 2010

Correction

The Merit Systems Protection Board is slated to hold its first oral argument in 27 years.  The announcement of the oral argument was made last week in the Federal Register.  The argument before the Merit Systems Protection Board will take place at the Court of Appeals for the Federal Circuit.

The MSPB announcement reads as follows:

U.S. MERIT SYSTEMS PROTECTION BOARD (MSPB) TO CONDUCT FIRST ORAL ARGUMENT IN 27 YEARS

On Tuesday, September 21, 2010, the MSPB will hear oral argument in the matters of Rhonda K. Conyers v. Department of Defense, MSPB Docket No. CH–0752–09–0925–I–1, and Devon H. Northover v. Department of Defense, MSPB Docket No. AT–0752–10–0184–I–1. The proceedings will take place at 10:00 a.m. at the United States Court of Appeals for the Federal Circuit, Room 201, 717 Madison Place, N.W., Washington, D.C. See 75 FR 56146, Sept. 15, 2010.

 

Conyers and Northover raise the question of whether, pursuant to 5 CFR part 732, the rule in Department of the Navy v. Egan, 484 U.S. 518, 530–31 (1988), limiting the scope of MSPB review of an adverse action based on the revocation of a security clearance, also applies to an adverse action involving an employee in a ‘‘non-critical sensitive’’ position due to the employee having been denied continued eligibility for employment in a sensitive position. The Board requested and received an advisory opinion from the Office of Personnel Management (OPM) in this matter. See 5 U.S.C. § 1204(e)(1)(A). The Board also invited and received amicus curiae briefs. See 75 FR 6728, Feb. 10, 2010.

 

The parties and the amici curiae will be allotted time at the hearing to present oral argument in this matter. The briefs submitted by the parties and the amici curiae, as well as OPM’s advisory opinion, are available for viewing on the MSPB’s website at http://www.mspb.gov/oralarguments. The MSPB also will make a recording of the oral argument available on its website. The public is welcome to attend this hearing for the sole purpose of observation. Any person attending this oral argument who requires special accessibility features, such as sign language interpretation, must inform MSPB of those needs in advance.

 

This is the first time the MSPB has conducted an oral argument in 27 years. Chairman Susan Tsui Grundmann, Vice Chairman Anne Wagner, and Member Mary Rose will utilize oral argument in cases like Conyers and Northover that present issues of special significance because of their broad potential impact on the Federal civil service and merit systems. Chairman Grundmann stated, “In an era of unprecedented Government transparency and openness, it is incumbent upon the Board to exercise its existing abilities to request amicus briefs and conduct oral argument in order to shed light on the issues, the debate, and the process. Doing so should result in the best decisions for Federal employees and agencies, and the American people.”

 

The U.S. Merit System Protection Board (MSPB) is an independent, quasi-judicial agency that protects Federal merit systems and the rights of individuals within those systems. The MSPB also conducts studies of the civil service and other merit systems in the Executive Branch.

 

The Federal Register announcement is available here: [Read].

Alice in Wonderland — Part II

September 17th, 2010

Alice in Wonderland made an encore appearance at the Federal Circuit recently during the oral argument of Daiichi Sankyo Co. v. Mylan Pharma, 2009-1511 (Fed. Cir. Sept. 9, 2010).  The panel was trying to assess whether one would have chosen an example in a patent reference as a motivation to modify another reference, when the example was the 118th example in the patent reference.  This prompted Judge Friedman to make the following analogy to Alice in Wonderland: [Listen].

References to Alice in Wonderland are made quite often in judicial opinions.  If you have access to Lexis, see “Wondering about Alice: Judicial References to Alice in Wonderland and Through the Looking Glass,” Parker B. Potter, Jr., 28 Whittier L. Rev. 175 (2006).

You can listen to the entire oral argument here: [Listen].

You can read the opinion here: [Read].

Federal Circuit Judges Heading to Japan in 2011

September 15th, 2010

rotated-tokyo1The Federal Circuit has posted an announcement on its web site that Chief Judge Rader and other judges will be holding a joint judicial conference with the Tokyo Intellectual Property High Court in Tokyo, Japan on May 12th and 13th, 2011.

The historic conference will offer judges the opportunity to explore common issues and learn from each other about intellectual property litigation.

Oral Arguments for the “2010 KSR Guidelines Update”

September 11th, 2010

The USPTO recently published its 2010 KSR Guidelines Update  in view of case law that has developed since KSR Int’l, Co. v. Teleflex, Inc. was decided by the US Supreme Court. Listed below are the charts from the guidelines with some additional information. Namely, I’ve added a  hyperlink to the court’s opinion, a column for the judges on the panel with the author of the opinion underlined, whether the teaching point could be deemed pro-inventor, and a link for listening to the oral argument.

Combining Prior Art Elements

 

 

In re Omeprazole Patent Litigation, 536 F.3d 1361 (Fed. Cir. 2008).

 

Even where a general method that could have been applied to make the claimed product was known and within the level of skill of the ordinary artisan, the claim may nevertheless be nonobvious if the problem which had suggested use of the method had been previously unknown

Lourie

Bryson

Gajarsa

 Yes

 Listen

Crocs, Inc. v. U.S. Int’l Trade Comm’n., 598 F.3d 1294 (Fed. Cir. 2010).

A claimed combination of prior art elements may be nonobvious where the prior art teaches away from the claimed combination and the combination yields more than predictable results.

Lourie

Rader

Prost

 Yes

Listen 

Sundance, Inc. v. DeMonte Fabricating Ltd., 550 F.3d 356 (Fed.Cir. 2008).

A claimed invention is likely to be obvious if it is a combination of known prior art elements that would reasonably have been expected to maintain their respective properties or functions after they have been combined. 

Dyk

Prost

Moore

 No

 Listen

 Ecolab, Inc. v. FMC Corp., 569 F.3d 1335 Fed. Cir. 2009).

A combination of known elements would have been prima facie obvious if an ordinarily skilled artisan would have recognized an apparent reason to combine those elements and would have known how to do so. 

Rader

Gajarsa

Dyk

 No

Listen 

 

Wyers v. Master Lock Co., No. 2009–1412, — F.3d—, 2010 WL 2901839 (Fed. Cir. July 22, 2010). 

The scope of analogous art is to be construed broadly and includes references that are reasonably pertinent to the problem that the inventor was trying to solve. Common sense may be used to support a legal conclusion of obviousness so long as it is explained with sufficient reasoning. 

Lourie

Linn

Dyk

No/Yes

 Listen

DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc., 567 F.3d 1314 (Fed. Cir. 2009).

Predictability as discussed in KSR encompasses the expectation that prior art elements are capable of being combined, as well as the expectation that the combination would have worked for its intended purpose.  An inference that a claimed combination would not have been obvious is especially strong where the prior art’s teachings undermine the very reason being proffered as to why a person of ordinary skill would have combined the known elements. 

Newman

Bryson

Linn

 No

 Listen

 

 Substituting One Known Element for Another 

In re ICON Health & Fitness, Inc., 496 F.3d 1374 (Fed. Cir. 2007).

 

When determining whether a reference in a different field of endeavor may be used to support a case of obviousness (i.e., is analogous), it is necessary to consider the problem to be solved.

 

Mayer

Schall

Prost

Yes

Listen

Agrizap, Inc. v. Woodstream Corp., 520 F.3d 1337 (Fed. Cir. 2008).

 

Analogous art is not limited to references in the field of endeavor of the invention, but also includes references that would have been recognized by those of ordinary skill in the art as useful for applicant’s purpose.

 

Bryson

Moore

Wolle*

No

Listen

Muniauction, Inc. v. Thomson Corp., 532 F.3d 1318 (Fed. Cir.

2008).

 

Because Internet and Web browser technologies had become commonplace for communicating and displaying information, it would have been obvious to adapt existing processes to incorporate them for those functions.

 

Gajarsa

Plager

Prost

No

Listen

Aventis Pharma Deutschland v. Lupin, Ltd., 499 F.3d 1293 (Fed.

Cir. 2007).

A chemical compound would have been obvious over a mixture containing that compound as well as other compounds where it was known or the skilled artisan had reason to believe that some desirable property of the mixture was derived in whole or in part from the claimed compound, and separating the claimed compound from the mixture was routine in the art.

 

Mayer

Linn

Robertson*

No

Listen

Eisai Co. Ltd. v. Dr. Reddy’s Labs., Ltd., 533 F.3d 1353 (Fed. Cir. 2008).

 

A claimed compound would not have been obvious where there was no reason to modify the closest prior art lead compound to obtain the claimed compound and the prior art taught that modifying the lead compound would destroy its advantageous property. Any known compound may serve as a lead compound when there is some reason for starting with that lead compound and modifying it to obtain the claimed

compound.

 

Rader

Linn

Prost

Yes/No

Listen

Procter & Gamble Co. v. Teva Pharmaceuticals USA, Inc., 566 F.3d 989 (Fed. Cir. 2009).

 

It is not necessary to select a single compound as a ‘‘lead compound’’ in order to support an obviousness rejection. However, where there was reason to select and modify the lead compound to obtain the claimed compound, but no reasonable expectation of success, the claimed compound would not have been obvious.

 

Mayer

Dyk

Huff*

No/Yes

Listen

Altana Pharma AG v. Teva

Pharms. USA, Inc., 566 F.3d 999

(Fed. Cir. 2009).

 

Obviousness of a chemical compound in view of its structural similarity to a prior art compound may be shown by identifying some line of reasoning that would have led one of ordinary skill in the art to select and modify a prior art lead compound in a particular way to produce the claimed compound. It is not

necessary for the reasoning to be explicitly found in the prior art of record, nor is it  necessary for the prior art to point to only a single lead compound.

 

Newman

Gajarsa

Ward*

No

Listen

 

 

*Visiting judge sitting by designation

 

 

 

 

 

The Obvious to Try Rationale

In re Kubin, 561 F.3d 1351 (Fed. Cir. 2009).

 

A claimed polynucleotide would have been obvious over the known protein that it encodes where the

skilled artisan would have had a reasonable expectation of success in deriving the claimed

polynucleotide using standard biochemical techniques, and the skilled artisan would have had a reason

to try to isolate the claimed polynucleotide. KSR applies to all technologies, rather than just the ‘‘predictable’’

arts.

 

Rader

Friedman

Linn

No

Listen

Takeda Chem. Indus. v.

Alphapharm Pty., Ltd., 492 F.3d 1350 (Fed. Cir. 2007).

 

A claimed compound would not have been obvious where it was not obvious to try to obtain it from a

broad range of compounds, any one of which could have been selected as the lead compound for further

investigation, and the prior art taught away from using a particular lead compound, and there was

no predictability or reasonable expectation of success in making the particular modifications necessary

to transform the lead compound into the claimed compound.

 

Lourie

Bryson

Dyk

Yes

Listen

Ortho-McNeil Pharmaceutical, Inc. v. Mylan Labs, Inc., 520  F.3d 1358 (Fed. Cir. 2008).

 

Where the claimed anti-convulsant drug had been discovered somewhat serendipitously in the course of

research aimed at finding a new anti-diabetic drug, it would not have been obvious to try to obtain a

claimed compound where the prior art did not present a finite and easily traversed number of potential

starting compounds, and there was no apparent reason for selecting a particular starting compound from

among a number of unpredictable alternatives.

 

Michel

Rader

Linn

Yes

Listen

Bayer Schering Pharma A.G. v. Barr Labs., Inc., 575 F.3d 1341 (Fed. Cir. 2009).

 

A claimed compound would have been obvious where it was obvious to try to obtain it from a finite and

easily traversed number of options that was narrowed down from a larger set of possibilities by the prior

art, and the outcome of obtaining the claimed compound was reasonably predictable.

 

Mayer

Friedman

———–

Newman(dissent)

No

Listen

Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075 (Fed. Cir. 2008).

 

A claimed isolated stereoisomer would not have been obvious where the claimed stereoisomer exhibits unexpectedly

strong therapeutic advantages over the prior art racemic mixture without the correspondingly

expected toxicity, and the resulting properties of the enantiomers separated from the racemic mixture

were unpredictable.

 

Newman

Lourie

Bryson

Yes

Listen

Rolls-Royce, PLC v. United Technologies Corp., 603 F.3d 1325

(Fed. Cir. 2010).

 

An obvious to try rationale may be proper when the possible options for solving a problem were known

and finite. However, if the possible options were not either known or finite, then an obvious to try rationale

cannot be used to support a conclusion of obviousness.

 

Michel

Rader

Schall

Yes

Listen

Perfect Web Techs., Inc. v. InfoUSA, Inc.,  587 F.3d 1324

(Fed. Cir. 2009).

 

Where there were a finite number of identified, predictable solutions and there is no evidence of unexpected

results, an obvious to try inquiry may properly lead to a legal conclusion of obviousness. Common

sense may be used to support a legal conclusion of obviousness so long as it is explained with sufficient

reasoning.

Linn

Dyk

Prost

No/Yes

Listen

 Consideration of Evidence

PharmaStem  Therapeutics, Inc. v. ViaCell, Inc., 491 F.3d 1342 (Fed. Cir. 2007).

 

Even though all evidence must be considered in an obviousness analysis, evidence of nonobviousness

may be outweighed by contradictory evidence in the record or by what is in the specification. Although a reasonable expectation of success is needed to support a case of obviousness, absolute predictability is

not required.

 

Bryson

Prost

——–

 

Newman (dissent)

No

Listen

In re Sullivan, 498 F.3d 1345 (Fed. Cir. 2007).

 

All evidence, including evidence rebutting a prima facie case of obviousness, must be considered when

properly presented.

 

Newman

Lourie

Gajarsa

Yes

Listen

Hearing Components, Inc. v. Shure Inc., 600 F.3d 1357 (Fed. Cir. 2010).

 

Evidence that has been properly presented in a timely manner must be considered on the record. Evidence

of commercial success is pertinent where a nexus between the success of the product and the

claimed invention has been demonstrated.

 

Lourie

Rader

Schall

Yes

Listen

Asyst Techs., Inc. v. Emtrak, Inc., 544 F.3d 1310 (Fed. Cir. 2008).

 

Evidence of secondary considerations of obviousness such as commercial success and long-felt need may

be insufficient to overcome a prima facie case of obviousness if the prima facie case is strong. An argument

for nonobviousness based on commercial success or long-felt need is undermined when there is a

failure to link the commercial success or long-felt need to a claimed feature that distinguishes over the

prior art.

 

Michel

Newman

Bryson

No

Listen

 

 

 

Sharon Barner Arguing at the Federal Circuit

September 1st, 2010

Prior to taking one of the top positions at the USPTO as Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the USPTO, Sharon Barner was in private practice in Chicago.  She has argued at least once before the United States Court of Appeals for the Federal Circuit. 

You can listen to her argument before the Federal Circuit in Automed Technologies v. Microfil, LLC, 2006-1620 (Fed. Cir. Jul. 16, 2007) here: [Listen].

You can read the court’s opinion in that case here: [Read].

Judge O’Malley’s Answers to Questions for the Record

August 31st, 2010

The Senate Judiciary Committee has posted Federal Circuit nominee Kathleen O’Malley’s answers to its written questions.  You may recall that she appeared before the committee to answer questions back on July 28, 2010.  If memory serves me correctly, the Senate Judiciary Committee asked no questions relating to patents during the in-person appearance or in the questions for the record.

Judge O’Malley’s written answers to the Senate Judicary Committee’s questions are available here: [Read].

Alice in Wonderland at the Federal Circuit

August 30th, 2010

Advocates at the Federal Circuit sometimes (although rarely) use poetry during oral argument.  In Figueroa v. U.S., 466 F.3d 1023 (Fed. Cir. 2006), a case from 2006  concerning the constitutionality of patent fees, one of the attorneys used verse from Alice in Wonderland plus his own original composition:  [Listen].

You can listen to the entire oral argument here: [Listen].

You can read the court’s opinion here: [Read].

Cybor Watch

August 27th, 2010

It has been almost four years since the Federal Circuit declined to take en banc review of the case Amgen, Inc. v. Hoechst Marion Roussel that would have allowed the court to review its en banc ruling in Cybor Corp v. FAS Techs., Inc., 138 F.3d 1448 (Fed. Cir. 1998).   In declining to hear the Amgen case en banc, several of the judges noted that when the right case came along, they would be willing to grant en banc review to reconsider Cybor.   [Read].

Judge Clevenger and Judge Moore recently made these comments which seemed to imply discontent with the Cybor precedent during the oral argument of Lincoln National Life Insurance Co. v. Transamerica Life Insurance Co., 2009-1403 (Fed. Cir. June 23, 2010): [Listen]. 

Judge Moore also made a comment about revisiting Cybor back in 2009 during the oral argument of Kara Technology, Inc. v. Stamps.com, Inc. [Listen].

And, you might recall that the court can take en banc review sua sponte.  They did so in Abbott Labs v. Sandoz, Inc., 566 F.3d 1282 (Fed. Cir. 2009) on the limited issue of product-by-process claims, for example.

One wonders if the time is now ripe and whether the vacancies on the court favor granting en banc review of Cybor

The Cybor decision is available here: [Read].

(I should note that I am not advocating an en banc review of Cybor — just curious if it is coming down the pike.)

Offers to Sell

August 26th, 2010

In Transocean v. Maersk, 2009-1556 (Fed. Cir. Aug. 18, 2010), the Federal Circuit addressed the issue of whether an offer to sell that is communicated outside the territorial boundaries of the United States  by the offeror to the offeree but for performance within the United States satisfies 35 USC §271(a)’s offer to sell provision.  The district court ruled that it did not.  The Federal Circuit reversed, stating:

Section 271(a) defines infringing conduct: “whoever without authority makes, uses, offers to sell, or sells any patented invention, within the United States. . . infringes the patent.” 35 U.S.C. § 271(a). An offer to sell is a distinct act of infringement separate from an actual sale. An offer to sell differs from a sale in that an offer to sell need not be accepted to constitute an act of infringement. See MEMC Elec. Materials, Inc. v. Mitsubishi Materials Silicon Corp., 420 F.3d 1369, 1376 (Fed. Cir. 2005). Moreover, the damages that would flow from an unac-cepted offer to sell and an actual sale would likely be quite different. See Timothy R. Holbrook, Liability for the “Threat of Sale”: Assessing Patent Infringement for Offer-ing to Sell an Invention and Implications for the On-Sale Patentability Bar and other Forms of Infringement, 43 Santa Clara L. Rev. 751, 791-92 (2003). We analyze an offer to sell under § 271(a) using traditional contract principles. Rotec Indus., Inc. v. Mitsubishi Corp., 215 F.3d 1246 (Fed. Cir. 2000). There is no dispute that there was an offer to sell in this case, but Maersk USA argues that the offer was made in Norway, not the United States, thereby absolving it of § 271(a) liability.

Maersk A/S (a Danish company) and Statoil ASA (a Norwegian company) negotiated the contract that is the subject of this alleged offer to sell. Their U.S. affiliates, Maersk USA and Statoil executed the contract in Norway. The contract included an “Operating Area” of the U.S. Gulf of Mexico. The district court held that because the negotiations and execution took place outside the U.S., this could not be an offer to sell within the United States under § 271(a).

Transocean argues that to hold that this contract be-tween two U.S. companies for performance in the U.S. is not an offer to sell within the U.S. simply because the contract was negotiated and executed abroad would be inconsistent with Lightcubes, LLC v. Northern Light Products, Inc., 523 F.3d 1353 (Fed. Cir. 2008) (holding that a foreign company cannot avoid liability for a sale by delivering the product outside the U.S. to a U.S. customer for importation). Transocean argues that a contract between two U.S. companies for delivery or performance in the U.S. must be an offer to sell within the United States under § 271(a).

Maersk USA argues that Rotec, 215 F.3d 1246 and MEMC, 420 F.3d 1369 require that, for there to be an offer to sell within the U.S., the offer activities must occur within the U.S. It argues that the negotiations and execution outside the U.S. preclude offer to sell liability in this case.

This case presents the question whether an offer which is made in Norway by a U.S. company to a U.S. company to sell a product within the U.S., for delivery and use within the U.S. constitutes an offer to sell within the U.S. under § 271(a). We conclude that it does. Sec-tion 271(a) states that “whoever . . . offers to sell . . . within the United States any patented invention . . . infringes.” In order for an offer to sell to constitute in-fringement, the offer must be to sell a patented invention within the United States. The focus should not be on the location of the offer, but rather the location of the future sale that would occur pursuant to the offer.

The offer to sell liability was added to the patent stat-ute to conform to the April 1994 Uruguay Round’s Trade-Related Aspects of Intellectual Property Agreement (TRIPS). The underlying purpose of holding someone who offers to sell liable for infringement is to prevent “generat-ing interest in a potential infringing product to the com-mercial detriment of the rightful patentee.” 3D Sys., Inc. v. Aarotech Labs., Inc., 160 F.3d 1373, 1379 (Fed. Cir. 1998). The offer must be for a potentially infringing article. Id. We are mindful of the presumption against extraterritoriality. Microsoft Corp. v. AT&T Corp., 550 U.S. 437, 441 (2007). “It is the general rule under United States patent law that no infringement occurs when a patented product is made and sold in another country.” Id. This presumption has guided other courts to conclude that the contemplated sale would occur within the United States in order for an offer to sell to constitute infringe-ment. See, e.g., Semiconductor Energy Lab. Co. v. Chi Mei Optoelectronics Corp., 531 F. Supp. 2d 1084, 1110-11 (N.D. Cal. 2007). We agree that the location of the con-templated sale controls whether there is an offer to sell within the United States.

The statute precludes “offers to sell . . . within the United States.” To adopt Maersk USA’s position would have us read the statute as “offers made within the United States to sell” or “offers made within the United States to sell within the United States.” First, this is not the statutory language. Second, this interpretation would exalt form over substance by allowing a U.S. company to travel abroad to make offers to sell back into the U.S. without any liability for infringement. See 3D Sys., 160 F.3d at 1379. This company would generate interest in its product in the U.S. to the detriment of the U.S. patent owner, the type of harm that offer to sell within the U.S. liability is meant to remedy. Id. These acts create a real harm in the U.S. to a U.S. patentee.

Neither Rotec nor MEMC preclude our determination that an offer by a U.S. company to sell a patented inven-tion to another U.S. company for delivery and use in the U.S. constitutes an offer to sell within the U.S. First, SEB S.A. v. Montgomery Ward & Co., 594 F.3d 1360, 1375 (Fed. Cir. 2010) contemplated whether the territorial reach of the offer to sell language had been decided by Rotec and concluded that it had not. The defendants in Rotec did argue that because the offer was made in China, not the U.S., they did not infringe. Rotec, 215 F.3d at 1251. And the Rotec court discussed the evidence regard-ing meetings and communications made in the United States. Id. at 1255. The Rotec court held that there was no offer to sell, not because of the location of the offer or of the ultimate sale, but rather because there was no evi-dence that an offer was communicated or conveyed by the defendants. Id. at 1255 (“None of this evidence, however, establishes any communication by Defendants with any third party.”). In concurrence, Judge Newman indicates that she would have instead decided the case on the ground that there was no offer which contemplated a sale within the U.S. Id. at 1259 (Newman, J., concurring). The MEMC case is even further attenuated as it did not even consider location of the offer or the contemplated sale, but instead held there was no offer to sell because the emails at issue, which contained only technical data and no price terms, cannot constitute an offer that could be made into a binding contract by acceptance. 420 F.3d at 1376.

We conclude that neither Rotec nor MEMC control this case. We hold that the district court erred because a contract between two U.S. companies for performance in the U.S. may constitute an offer to sell within the U.S. under § 271(a). The fact that the offer was negotiated or a contract signed while the two U.S. companies were abroad does not remove this case from statutory liability. We therefore vacate the district court’s summary judgment of noninfringement.4

The offer to sell issue was discussed with appellant’s counsel during oral argument and can be heard here: [Listen].

The entire oral argument can be heard here: [Listen].

The court’s opinion is available here: [Read].

Chief Judge Rader’s Portrait Presentation

August 24th, 2010

This might be of interest to patent practitioners in the D.C. area:rportrait11

“At Least” and the Specific Exclusion Principle as a Limit on the Doctrine of Equivalents

August 21st, 2010

The Federal Circuit addressed the doctrine of equivalents recently  in the case of Adams Respiratory Therapeutics, Inc. et al. v. Perrigo Co. et al., 2010-1246 (Fed. Cir. Aug. 5, 2010).  One issue facing the panel was whether the term “at least 3500 hr*ng/mL” can be interpreted under the doctrine of equivalents to be a value less than 3500 hr*ng/mL.

The panel chose to read the language “at least 3500 hr*ng/mL”  as the simplest way of expressing a range that is “greater than or equal to 3500 hr*ng/mL.”  See Adams at 18.   However, one might make the alternative argument that “at least 3500 hr*ng/mL” is actually the simplest way of expressing  a range that is “not less than 3500 hr*ng/mL.”  Moreover, this would comport with the Patent Office’s preference for avoiding the use of negative limitations in claims.  If such an interpretation is adopted for the “at least 3500 hr*ng/mL” language, the “specific exclusion principle” might serve to limit application of the doctrine of equivalents and require a different outcome than that reached by the panel.

For background, the Adams panel concluded:

We previously determined that the doctrine of equivalents may apply to claims containing specific numeric ranges. See Philips, 505 F.3d at 1378 (concluding that “resort to the doctrine of equivalents is not foreclosed with respect to the claimed concentration range”); Abbott, 287 F.3d at 1107-08 (“The fact that a claim recites numeric ranges does not, by itself, preclude Abbott from relying on the doctrine of equivalents.”); Jeneric/Pentron, Inc. v. Dillon Co., 205 F.3d 1377, 1383 (Fed. Cir. 2000) (noting that “the district court will have the opportunity to adjudicate fully the merits of infringement under the doctrine of equivalents” of a claim to composition comprising specific weight percentages of various oxides). In Philips, we addressed a claim requiring the presence of a halogen “in a quantity between 10-6 and 10-4 umol/mm3,” which we construed as “between 1 × 10-6 and 1 × 10-4 umol/mm3.” 505 F.3d at 1376. We rejected the argument that applying the doctrine of equivalents would vitiate this claim limitation because “[a] reasonable juror could make a finding that a quantity of halogen outside that [claimed] range is insubstantially different from a quantity within that range without `ignor[ing] a material limitation’ of the patent claim.” Id. at 1379. We thus concluded that the doctrine of equivalents was not foreclosed with respect to the claimed range. Id. at 1380. Similarly, in Abbott, we concluded that the doctrine of equivalents could apply to a claim requiring a 68.8% to 94.5% by weight of a phospholipid. 287 F.3d at 1107-08. Abbott’s expert testified that 95% phospholipid “would be exactly the same as the claimed phospholipid.” Id. at 1107. We concluded that “[a]lthough this testimony expands the upper limit beyond the range literally recited by the claim, it does not eliminate the upper limit altogether.” Id. We therefore concluded that infringement under the doctrine of equivalents would not eliminate the upper limit of the phospholipid claim. Id. “The fact that a claim recites numeric ranges does not, by itself, preclude Abbott from relying on the doctrine of equivalents.” Id. at 1107-08. Finally, in Jeneric, the district court denied Jeneric’s request for a preliminary injunction, concluding that Jeneric failed to establish a likelihood of success on infringement under the doctrine of equivalents. 205 F.3d at 1383. Although we affirmed the court’s denial of Jeneric’s request for a preliminary injunction, we indicated that the record on infringement under the doctrine of equivalents was premature. Id. at 1384. We noted that the accused composition contained 0.041% of lithium oxide, which fell outside the claimed range of 0.5% to 3%. Id. We concluded that “[a] full record will show whether that difference is insubstantial.” Id. We are bound by these cases which hold that the doctrine of equivalents can apply to a range—a numerical limitation in a claim. The mere existence of a numerical value or range in a claim, absent more limiting language in the intrinsic record, does not preclude application of the doctrine of equivalents.

Adams Respiratory Therapeutics, Inc. et al. v. Perrigo Co. et al., slip op. at 17-18.

 

This explanation by the panel is logical based on the cases they rely upon.  But, other cases would suggest that a different result could also be reached.  For example, the panel’s decision does not address the Athletic Alternatives, Inc. v. Prince Mfg., Inc. case.  And, the panel’s decision does not address the “specific exclusion principle” that is a corollary to the All Elements Rule.

Athletic Alternatives, Inc. v. Prince Mfg., Inc.

 In the Athletic Alternatives, Inc. v. Prince Mfg., Inc., 73 F.3d 1573 (Fed. Cir. 1996) case, a case that concerned the stringing of tennis racquets, the Federal Circuit construed a claim term to mean “at least three values”:

We conclude that Claim 1 of the ‘097 patent includes the limitation that the splay-creating string end offset distance take on at least three values, i.e., a minimum, a maximum, and at least one intermediate value. We thus affirm the district court’s conclusion that Claim 1 does not literally read on the Vortex racket.

Athletic Alternatives, Inc. v. Prince Mfg., Inc., at 1581.

In applying the doctrine of equivalents to this term, the court indicated that “at least three” specifically excluded two and was thus barred by the doctrine of equivalents:

As a corollary to the “all limitations” rule discussed above, we have held that “the concept of equivalency cannot embrace a structure that is specifically excluded from the scope of the claims.” Dolly, Inc., 16 F.3d at 400, 29 USPQ2d at 1771. Applying this formulation to the undisputed facts of the instant case, we conclude that the intermediate offset distance required by the properly construed claim cannot have an equivalent in a racket with only two offset distances. In other words, the two-distance splayed string system was “specifically excluded from the scope of the claims.” Id. To hold Prince liable for infringement of Claim 1 of the ‘097 patent for its production and sale of the Vortex racket would thus run afoul of our holding in Dolly, Inc. and the “all limitations” rule from which it derives. As a result, AAI is precluded as a matter of law from successfully asserting that the Vortex racket infringes Claim 1 of the ‘097 patent under the doctrine of equivalents.

Athletic Alternatives, Inc. v. Prince Mfg., Inc., at 1583.

Quite succinctly, the Athletic Alternatives majority concluded that the language “at least three” excluded “at least two.”

The Specific Exclusion Principle

The “specific exclusion principle” was explained in the Scimed v. Advanced Cardiovascular, 242 F.3d 1337 (Fed. Cir. 2001) case:

A particular structure can be deemed outside the reach of the doctrine of equivalents because that structure is clearly excluded from the claims whether the exclusion is express or implied. In Moore, U.S.A., Inc. v. Standard Register Co., 229 F.3d 1091, 56 USPQ2d 1225 (Fed.Cir.2000), for example, the court considered a claim to a mailer-type business form in which the longitudinal strips of adhesive extend “the majority of the lengths” of the longitudinal margins of the form. The patentee argued that the accused form, in which the longitudinal strips of adhesive extended a minority of the length of the longitudinal margin of the form, infringed under the doctrine of equivalents. The court rejected the argument, holding that “it would defy logic to conclude that a minority — the very antithesis of a majority — could be insubstantially different from a claim limitation requiring a majority, and no reasonable juror could find otherwise.” 229 F.3d at 1106, 56 USPQ2d at 1236. Similarly, in Eastman Kodak Co. v. Goodyear Tire & Rubber Co., 114 F.3d 1547, 42 USPQ2d 1737 (Fed.Cir.1997), the patent claimed a process that included crystallizing a particular substance at high temperature “under an inert gas atmosphere.” The patentee argued that certain of the accused processes, which used “heated air” rather than “an inert gas atmosphere” infringed under the doctrine of equivalents. The court rejected that argument, explaining that “the claim language specifically excludes reactive gases — such as `heated air’ — from the scope of the claims” and in light of that specific exclusion, the accused processes could not infringe under the doctrine of equivalents. 114 F.3d at 1561, 42 USPQ2d at 1747. In each of these cases, by defining the claim in a way that clearly excluded certain subject matter, the patent implicitly disclaimed the subject matter that was excluded and thereby barred the patentee from asserting infringement under the doctrine of equivalents.

The court did effectively the same thing in Sage Products, Inc. v. Devon Industries, Inc., 126 F.3d 1420, 44 USPQ2d 1103 (Fed.Cir.1997). In that case, the claim was to a syringe disposal container having an elongated slot at the top of the container body and a “first constriction extending over said slot.” Although those limitations did not literally read on the accused device, the patentee argued that the device infringed under the doctrine of equivalents. The court rejected that argument, noting that the claim

defines a relatively simple structural device. No subtlety of language or complexity of the technology, nor any subsequent change in the state of the art, such as later-developed technology, obfuscated the significance of this limitation at the time of its incorporation into the claim…. If Sage desired broad patent protection for any container that performed a function similar to its claimed container, it could have sought claims with fewer structural encumbrances…. [A]s between the patentee who had a clear opportunity to negotiate broader claims but did not do so, and the public at large, it is the patentee who must bear the cost of its failure to seek protection for this foreseeable alteration of its claimed structure.

126 F.3d at 1425, 44 USPQ2d at 1107. Thus, the court determined that because the scope of the claim was limited in a way that plainly and necessarily excluded a structural feature that was the opposite of the one recited in the claim, that different structure could not be brought within the scope of patent protection through the doctrine of equivalents. See Ethicon Endo-Surgery, Inc. v. U.S. Surgical Corp., 149 F.3d 1309, 1317, 47 USPQ2d 1272, 1277 (Fed.Cir.1998) (subject matter is “specifically excluded” from coverage under the doctrine of equivalents if its inclusion is “inconsistent with the language of the claim”).

Finally, in Athletic Alternatives, Inc. v. Prince Manufacturing, Inc., 73 F.3d 1573, 37 USPQ2d 1365 (Fed.Cir.1996), the court addressed a claim directed to a system for stringing tennis rackets with splayed strings. The court construed the claim to require that the stringing system produce rackets with at least three different splay-creating offset distances for the strings. Having construed the claim in that manner, the court held that, for purposes of the doctrine of equivalents, “the properly construed claim cannot have an equivalent in a racket with only two offset distances,” i.e., the two-distance splayed string system was “specifically excluded from the scope of the claims.” 73 F.3d at 1582, 37 USPQ2d at 1373 (quoting Dolly, 16 F.3d at 400, 29 USPQ2d at 1771). See also Zodiac Pool Care, Inc. v. Hoffinger Indus., Inc., 206 F.3d 1408, 1416, 54 USPQ2d 1141, 1147 (Fed.Cir.2000) (“[N]o reasonable jury could find that a stop which extends to the peripheral edge of a disk is equivalent to one that is `substantially inward’ of the very same disk.”); Wiener v. NEC Elecs., Inc., 102 F.3d 534, 541, 41 USPQ2d 1023, 1029 (Fed.Cir.1996) (doctrine of equivalents does not extend to an accused device in which “the required structure is specifically excluded” by the patent).

The principle articulated in these cases is akin to the familiar rule that the doctrine of equivalents cannot be employed in a manner that wholly vitiates a claim limitation. See Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 29-30, 117 S.Ct. 1040, 137 L.Ed.2d 146 1347*1347 (1997); Athletic Alternatives, 73 F.3d at 1582, 37 USPQ2d at 1373 (“specific exclusion” principle is “a corollary to the `all limitations’ rule”). Thus, if a patent states that the claimed device must be “non-metallic,” the patentee cannot assert the patent against a metallic device on the ground that a metallic device is equivalent to a non-metallic device. The unavailability of the doctrine of equivalents could be explained either as the product of an impermissible vitiation of the “non-metallic” claim limitation, or as the product of a clear and binding statement to the public that metallic structures are excluded from the protection of the patent. As the court made clear in Sage, the foreclosure of reliance on the doctrine of equivalents in such a case depends on whether the patent clearly excludes the asserted equivalent structure, either implicitly or explicitly.

In that respect, this case is an even stronger one for not applying the doctrine of equivalents than cases such as Dolly, Sage, Eastman Kodak, Moore, and Athletic Alternatives. Each of the SciMed patents specifically recognized and disclaimed the dual lumen structure, making clear that the patentee regarded the dual lumen configuration as significantly inferior to the coaxial lumen configuration used in the invention. Where such an explicit disclaimer is present, the principles of those cases apply a fortiori, and the patentee cannot be allowed to recapture the excluded subject matter under the doctrine of equivalents without undermining the notice function of the patent. As the court observed in Sage, the patentee had an opportunity to draft the patent in a way that would make clear that dual lumens as well as coaxial lumens were within the scope of the invention, but the patentee did just the opposite, leaving competitors and the public to draw the reasonable conclusion that the patentee was not seeking patent protection for catheters that used a dual lumen configuration. Under these circumstances, the district court was justified in concluding that a reasonable jury could not find that the accused devices infringe the SciMed patents under the doctrine of equivalents.

Scimed at 1345-47.

 

More recently in Trading Technologies Intl., Inc. v. Espeed et al., 595 F.3d 1340 (Fed. Cir. 2010) the Federal Circuit cited the Scimed case stating:

 The all-elements rule requires this court to consider “the totality of circumstances of each case and determine whether the alleged equivalent can be fairly characterized as an insubstantial change from the claimed subject matter without rendering the pertinent limitation meaningless.” Freedman Seating Co. v. Am. Seating Co., 420 F.3d 1350, 1359 (Fed.Cir.2005). In other words, this rule empowers a court to perform again the standard “insubstantial variation” test for equivalency, but this time as a question of law. Claim vitiation applies when there is a “clear, substantial difference or a difference in kind” between the claim limitation and the accused product. Id. at 1360. It does not apply when there is a “subtle difference in degree.” Id.

In this case, the trial court considered whether an occasional automatic re-centering of the price axis in Dual Dynamic is equivalent to “never chang[ing] positions unless by manual re-centering or re-positioning.” The court determined that the automatic re-centering would render the claim limitation “static”—synonymous with only manual re-centering—meaningless. The trial court’s construction of the claim limitation “static” specifically excludes any automatic re-centering. See SciMed Life Sys. v. Advanced Cardiovacsular Sys., 242 F.3d 1337, 1347 (Fed.Cir.2001) (“[I]f a patent states that the claimed device must be `non-metallic,’ the patentee cannot assert the patent against a metallic device on the ground that a metallic device is equivalent to a non-metallic device.”).

Thus, if one were to interpret the claim language “at least 3500 hr*ng/mL” to mean “not less than 3500 hr*ng/mL,” the specific exclusion principle would seem to prevent the patent from being expanded under the DOE to cover the range that is less than 3500 hr*ng/mL  — just as the Scimed case counsels against interpreting non-metallic to be expanded to include metallic, and the Moore USA case counsels against majority being expanded to include minority, and Eastern Kodak counsels against inert being expanded to include non-inert .     

 The famous language from Sage Products rings true when applied to the use of the claim language “at least”:

[A]s between the patentee who had a clear opportunity to negotiate broader claims but did not do so, and the public at large, it is the patentee who must bear the cost of its failure to seek protection for this foreseeable alteration of its claimed structure.

 

“Each of a plurality”

August 19th, 2010

Karen Hazzah noted on her All Things Pros blog on July 21st, the results of the Ex Parte Jourdan (Intel) appeal.  It is worth highlighting  again as it concerned the language “each of a plurality.”  

Given the prevalence of this language (as well as the language “each of the plurality . . .”)  in computer system claims, I think it will be a frequent  point of contention in the future — particularly during patent litigation.

The illustrative claim at issue read as follows:

ILLUSTRATIVE CLAIM

1. A method comprising:

assigning an identification number (ID) to each of a plurality of micro-operations (uops) to identify a branch path to which the uop belongs;

determining whether one or more branches are predicted correctly;

determining which of the one or more branch paths are dependent on a mispredicted branch; and

determining whether one or more of the plurality of uops belong to a branch path that is dependent on the mispredicted branch based on their assigned IDs.

The Board ruled as follows:

The Appellants argue that “the cited claim language as a whole explicitly requires that a separate ID is assigned ‘to each of a plurality of micro-operations (uops)’ (emphasis added).” (Reply Br. 2.) “[T]he PTO gives claims their ‘broadest reasonable interpretation.'” In re Bigio, 381 F.3d 1320, 1324 (Fed. Cir. 2004) (quoting In re Hyatt, 211 F.3d 1367, 1372 (Fed. Cir. 2000)). “Moreover, limitations are not to be read into the claims from the specification.” In re Van Geuns, 988 F.2d 1181, 1184 (Fed. Cir. 1993) (citing In re Zletz, 893 F.2d 319, 321 (Fed. Cir. 1989)).

 

Here, claim 1 does not require that the ID assigned to each microoperation be “separate.” i.e., unique. We refuse to read such a requirement into the representative claim. Assigning the same ID to each microoperation in one of the reference’s instruction streams is enough to anticipate the disputed limitations. Based on the aforementioned facts and analysis, therefore, we conclude that the Examiner did not err in finding that Sharangpani assigns an ID to each of a plurality of micro-operations as required by representative claim 1.

For other issues that arise from use of the word “each,” see these previous posts: [Link] and [Link].